Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 45

1.

Comment on 'Validation of a contemporary prostate cancer grading system using prostate cancer death as outcome'.

Dell'Oglio P, Stabile A, Gandaglia G, Briganti A.

Br J Cancer. 2017 Jan;116(3):e3. doi: 10.1038/bjc.2016.346. No abstract available.

PMID:
27780195
2.

Economic evaluation of treatments for patients with localized prostate cancer in Europe: a systematic review.

Becerra V, Ávila M, Jimenez J, Cortes-Sanabria L, Pardo Y, Garin O, Pont A, Alonso J, Cots F, Ferrer M; Multicentric Spanish Group of Clinically Localized Prostate Cancer..

BMC Health Serv Res. 2016 Oct 3;16(1):541.

3.

Fractionated radiation exposure amplifies the radioresistant nature of prostate cancer cells.

McDermott N, Meunier A, Mooney B, Nortey G, Hernandez C, Hurley S, Lynam-Lennon N, Barsoom SH, Bowman KJ, Marples B, Jones GD, Marignol L.

Sci Rep. 2016 Oct 5;6:34796. doi: 10.1038/srep34796.

4.

Comparisons of regular and on-demand regimen of PED5-Is in the treatment of ED after nerve-sparing radical prostatectomy for Prostate Cancer.

Qiu S, Tang Z, Deng L, Liu L, Han P, Yang L, Wei Q.

Sci Rep. 2016 Sep 9;6:32853. doi: 10.1038/srep32853.

5.

Incorporation of tissue-based genomic biomarkers into localized prostate cancer clinics.

Moschini M, Spahn M, Mattei A, Cheville J, Karnes RJ.

BMC Med. 2016 Apr 4;14:67. doi: 10.1186/s12916-016-0613-7. Review.

6.

Recent decline in prostate cancer incidence in the United States, by age, stage, and Gleason score.

Herget KA, Patel DP, Hanson HA, Sweeney C, Lowrance WT.

Cancer Med. 2016 Jan;5(1):136-41. doi: 10.1002/cam4.549.

7.

Linking obesogenic dysregulation to prostate cancer progression.

Taylor RA, Lo J, Ascui N, Watt MJ.

Endocr Connect. 2015 Dec;4(4):R68-80. doi: 10.1530/EC-15-0080. Review.

8.

Loss of STK11 expression is an early event in prostate carcinogenesis and predicts therapeutic response to targeted therapy against MAPK/p38.

Grossi V, Lucarelli G, Forte G, Peserico A, Matrone A, Germani A, Rutigliano M, Stella A, Bagnulo R, Loconte D, Galleggiante V, Sanguedolce F, Cagiano S, Bufo P, Trabucco S, Maiorano E, Ditonno P, Battaglia M, Resta N, Simone C.

Autophagy. 2015 Nov 2;11(11):2102-2113.

9.

Clinical outcomes of helical tomotherapy for super-elderly patients with localized and locally advanced prostate cancer: comparison with patients under 80 years of age.

Okonogi N, Katoh H, Kawamura H, Tamaki T, Kaminuma T, Murata K, Ohkubo Y, Takakusagi Y, Onishi M, Sekihara T, Okazaki A, Nakano T.

J Radiat Res. 2015 Nov;56(6):889-96. doi: 10.1093/jrr/rrv040.

11.

Plasma carotenoids and tocopherols in relation to prostate-specific antigen (PSA) levels among men with biochemical recurrence of prostate cancer.

Antwi SO, Steck SE, Zhang H, Stumm L, Zhang J, Hurley TG, Hebert JR.

Cancer Epidemiol. 2015 Oct;39(5):752-62. doi: 10.1016/j.canep.2015.06.008.

12.

Dose-Escalated Robotic SBRT for Stage I-II Prostate Cancer.

Meier R.

Front Oncol. 2015 Apr 7;5:48. doi: 10.3389/fonc.2015.00048. Review.

13.

Versican is a potential therapeutic target in docetaxel-resistant prostate cancer.

Arichi N, Mitsui Y, Hiraki M, Nakamura S, Hiraoka T, Sumura M, Hirata H, Tanaka Y, Dahiya R, Yasumoto H, Shiina H.

Oncoscience. 2015 Mar 2;2(2):193-204.

14.

Fifteen-year Outcomes Following Conservative Management Among Men Aged 65 Years or Older with Localized Prostate Cancer.

Lu-Yao GL, Albertsen PC, Moore DF, Lin Y, DiPaola RS, Yao SL.

Eur Urol. 2015 Nov;68(5):805-11. doi: 10.1016/j.eururo.2015.03.021.

15.

Impact of stage migration and practice changes on high-risk prostate cancer: results from patients treated with radical prostatectomy over the last two decades.

Fossati N, Passoni NM, Moschini M, Gandaglia G, Larcher A, Freschi M, Guazzoni G, Sjoberg DD, Vickers AJ, Montorsi F, Briganti A.

BJU Int. 2016 May;117(5):740-7. doi: 10.1111/bju.13125.

PMID:
25787671
16.

Genetic variants in the Hippo pathway predict biochemical recurrence after radical prostatectomy for localized prostate cancer.

Huang CY, Huang SP, Lin VC, Yu CC, Chang TY, Juang SH, Bao BY.

Sci Rep. 2015 Feb 24;5:8556. doi: 10.1038/srep08556.

17.

African Americans' Perceptions of Prostate-Specific Antigen Prostate Cancer Screening.

Hunter JC, Vines AI, Carlisle V.

Health Educ Behav. 2015 Aug;42(4):539-44. doi: 10.1177/1090198114566453.

18.

Potential upstream regulators of cannabinoid receptor 1 signaling in prostate cancer: a Bayesian network analysis of data from a tissue microarray.

Häggström J, Cipriano M, Forshell LP, Persson E, Hammarsten P, Stella N, Fowler CJ.

Prostate. 2014 Aug;74(11):1107-17. doi: 10.1002/pros.22827.

19.

Correlation of HOXD3 promoter hypermethylation with clinical and pathologic features in screening prostate biopsies.

Chen LN, Rubin RS, Othepa E, Cer C, Yun E, Agarwal RP, Collins BT, McGeagh K, Pahira J, Bandi G, Kowalczyk K, Kumar D, Dritschilo A, Collins SP, Bostwick DG, Lynch JH, Suy S.

Prostate. 2014 May;74(7):714-21.

20.

Clinical presentation of prostate cancer in black South Africans.

Tindall EA, Monare LR, Petersen DC, van Zyl S, Hardie RA, Segone AM, Venter PA, Bornman MS, Hayes VM.

Prostate. 2014 Jun;74(8):880-91. doi: 10.1002/pros.22806.

Supplemental Content

Support Center